Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Boehringer Ingelheim
QuintilesIMS
McKinsey
Healthtrust
Chinese Patent Office

Generated: May 23, 2019

DrugPatentWatch Database Preview

Nevirapine - Generic Drug Details

« Back to Dashboard

What are the generic sources for nevirapine and what is the scope of nevirapine patent protection?

Nevirapine is the generic ingredient in three branded drugs marketed by Aurobindo, Cipla, Boehringer Ingelheim, Alvogen Malta, Apotex Inc, Aurobindo Pharma Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Sandoz Inc, Tech Organized, Hetero Labs Ltd Iii, Micro Labs Ltd, Mylan Labs, Prinston Inc, and Strides Pharma, and is included in twenty-six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Nevirapine has thirty-two patent family members in twenty-seven countries.

There are twenty drug master file entries for nevirapine. Sixteen suppliers are listed for this compound. There are seven tentative approvals for this compound.

Medical Subject Heading (MeSH) Categories for nevirapine
Synonyms for nevirapine
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one
11-cyclopropyl-4-methyl-5H-dipyrido[2,3-b:3',2'-e][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5H-dipyrido[3,2-b
11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
129618-40-2
1vrt
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0;{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0(3),]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
2hny
5H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 5,11-dihydro-11-cyclopropyl-4-methyl-
618N402
6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
99DK7FVK1H
AB0013383
AB00393001_16
AB00393001_17
AB00393001-13
AB00393001-15
AB07544
AB2000266
AC-643
AC1L1I81
AJ-08226
AK143126
AKOS005504351
ALBB-027264
AN-15635
BBL010768
BC206673
BCP05587
BDBM1434
BI-RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
C07263
C15H14N4O
CAS-129618-40-2
CCG-100939
CHEBI:63613
CHEMBL57
CPD000048458
CS-2252
CTK8E7455
D00435
DB00238
DSSTox_CID_10787
DSSTox_GSID_31797
DSSTox_RID_78889
DTXSID7031797
F2173-0607
FT-0607215
H954
HMS2051J09
HMS2231O23
HMS3264D21
HMS3371E03
HMS3393J09
HMS3655I08
HMS3715B10
HSDB 7164
HY-10570
I02-0310
KB-64802
KS-00000KZF
KS-5019
LS-2289
MCULE-8608154492
MFCD00866928
MFCD00866928 (98%)
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MLS001424058
MLS006011423
MolPort-002-507-817
N0922
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NC00189
NCGC00065890-02
NCGC00065890-03
NCGC00065890-04
NCGC00065890-05
NCGC00065890-07
NCGC00258324-01
NEV
Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard
Nevirapine (JAN/USP/INN)
Nevirapine (Viramune)
Nevirapine [USAN:INN]
Nevirapine [USAN:USP:INN:BAN]
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine anhydrous
Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard
Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard
Nevirapine solution, 1.0 mg/mL in methanol, certified reference material
Nevirapine, 98%
Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material
Nevirapine,(S)
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NQDJXKOVJZTUJA-UHFFFAOYSA-N
NSC 641530
NSC-641530
NSC-759902
NSC641530
NSC759902
NVP
Opera_ID_934
Pharmakon1600-01503842
R3924
RL01415
RT-014690
S1742
SAM001246551
SC-17266
SCHEMBL3318
SMR000048458
ST24038235
STK580320
SW197569-2
SY009679
Tox21 110982
Tox21_110982
Tox21_110982_1
Tox21_200770
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune IR
Viramune XR
Viramune;BI-RG 587
Viramune(TM)
Z1695906730
ZB000592
ZINC4778
Generic filers with tentative approvals for NEVIRAPINE
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial50MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial200MGTABLET; ORAL
➤ Try a Free Trial➤ Try a Free Trial200MGTABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

US Patents and Regulatory Information for nevirapine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc NEVIRAPINE nevirapine TABLET, EXTENDED RELEASE;ORAL 206271-001 Nov 9, 2015 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE nevirapine SUSPENSION;ORAL 020933-001 Sep 11, 1998 AA RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Aurobindo NEVIRAPINE nevirapine TABLET;ORAL 077521-001 May 22, 2012 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for nevirapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim VIRAMUNE nevirapine TABLET;ORAL 020636-001 Jun 21, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE nevirapine SUSPENSION;ORAL 020933-001 Sep 11, 1998 ➤ Try a Free Trial ➤ Try a Free Trial
Boehringer Ingelheim VIRAMUNE XR nevirapine TABLET, EXTENDED RELEASE;ORAL 201152-001 Mar 25, 2011 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for nevirapine

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0429987 99C0019 France ➤ Try a Free Trial PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
0429987 C990022 Netherlands ➤ Try a Free Trial PRODUCT NAME: NEVIRAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NATL REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION: CH 54393 19971223
0429987 18/1999 Austria ➤ Try a Free Trial PRODUCT NAME: NEVIRAPINE; REGISTRATION NO/DATE: EU/1/97/055/001 19980205
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
Mallinckrodt
Accenture
Boehringer Ingelheim
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.